It was first approved in 2015 by the Food and Drug Administration and the European Medicines Agency after a pivotal trial in postmenopausal women with estrogen-positive, human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer [1]. Here, ERBB2 is linked to breast cancer.